PAVmed Inc. (PAVM)
Nasdaq: PAVM · Surgical & Medical Instruments & Apparatus · New York, NY · filing with the SEC since 2014
Who owns PAVmed Inc.
As filed with the SECHolders of 5% or more
9
Dana Carrera holds 15.3% of Common Stock, par value $0.001 per share, as its SCHEDULE 13G/A filed Apr 14, 2026 says.
Directors and officers
10
report now, of 18 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 9 named at left.
Holders of 5% or moreshare of the class, as filed
Dana Carrera
SCHEDULE 13G/A · filed Apr 14, 2026 · Common Stock, par value $0.001 per share · 14.3% in Apr 3, 2026
Two Seas Capital LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, $0.001 par value per share
Ayrton Capital LLC
SCHEDULE 13G/A · filed May 11, 2026 · Common Stock, $0.001 par value per share · 9.9% in Feb 13, 2025
Scopia Holdings LLC
SCHEDULE 13G · filed Apr 13, 2026 · Common Stock, par value $0.001 per share
First Manhattan Co. LLC.
SCHEDULE 13G · filed May 14, 2026 · Common Stock, Par Value $0.001 Per Share · 4.3% in May 15, 2025
Nagelberg David S
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, par value $0.001 per share · 8.6% in Apr 8, 2026
Sargent Investment Group, LLC
SCHEDULE 13G · filed Aug 14, 2025 · Common
Dols Scott V.
SCHEDULE 13G · filed Apr 8, 2026 · Common Stock, par value $0.001 per share
Aklog Lishan
SCHEDULE 13D · filed Apr 9, 2026 · Common Stock, par value $0.001 per share
Kallman Craig
SCHEDULE 13G/A · filed Oct 23, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6% in Apr 3, 2026
What PAVM reports owning in othersstakes of 5% or more, and other ties
Lucid Diagnostics Inc. LUCD
SCHEDULE 13D/A · filed Feb 9, 2026 · Common Stock, par value $0.001 per share
Other ties the annual report names
Veris Health
An entity · consolidated entity, legal entity · owns, named in the 10-K filed Mar 27, 2026
Lucid Diagnostics
An investee · consolidated entity, investee · invested in, named in the 10-K filed Mar 27, 2026
16 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 27, 2026.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2022 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.